Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic VEGF Dynamics with Ranibizumab vs Aflibercept in DME
NCT02258009Phase 4Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Planned start Oct 2015; status: withdrawn.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02258009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258009.